

ABT-263 (Navitoclax)

Cat. # F7140, F7141

- Also Known as:** 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[[trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide
- Formula:** $C_{47}H_{55}ClF_3N_5O_6S_3$
- MW:** 974.61 Da
- CAS No.:** 923564-51-6
- Source:** Synthetic
- Form:** Lyophilized powder
- Solubility:** > 20 mg/ml in DMSO
- Working Condition:** 1 μ M in cell culture assay
- Concentration:** N/A
- Quality Assurance:** >98% by HPLC and NMR
- Description:** ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with $K_i \sim 0.5$ nM, 1 nM and 1 nM in cell-free assays. ABT-263 blocks the Bcl-2/Bcl-xL interactions, thereby promoting apoptosis.
- Storage:** Eligible for room temperature shipping. Store at -80°C upon receiving; avoid multiple freeze-thaw cycles after dissolving in DMSO.
- Note:** Briefly spin the tube before removing the cap.
- Literature:** Tse C, *et al.* (2008) Cancer Res. 68(9), 3421-3428.

